June 28, 2018 Endpoints News As Alexion fields applications for ALXN1210, a rival aims for the crown with h… June 27, 2018 RARE Daily Apellis Pharmaceuticals Enrolls First Patient in Late-Stage Trial of Challenger… May 8, 2018 PharmExec.com Bridging Science & Strategy: An Investor’s Eye April 1, 2018 Retinal Physician RETINA CONVERSATIONS: A Conversation With Cedric Francois, MD, PhD February 23, 2018 BioPharma Dive Apellis touts new data for eye drug hopeful January 25, 2018 Healio, Ocular Surgery News Phase 3 trial of Apellis' geographic atrophy treatment to begin this year January 17, 2018 OIS Life After the IPO: What Does Apellis Have Planned After Raising $170m from Pub… November 9, 2017 FierceBiotech Chasing Alexion, Apellis hits the start button for $150M IPO August 25, 2017 FierceBiotech Apellis sets up another phase 3 program for lead drug APL-2 August 24, 2017 Endpoints News On a roll, Apellis adds positive PhII C3 data for AMD drug, preps for PhIII
June 28, 2018 Endpoints News As Alexion fields applications for ALXN1210, a rival aims for the crown with h…
June 27, 2018 RARE Daily Apellis Pharmaceuticals Enrolls First Patient in Late-Stage Trial of Challenger…
January 25, 2018 Healio, Ocular Surgery News Phase 3 trial of Apellis' geographic atrophy treatment to begin this year
January 17, 2018 OIS Life After the IPO: What Does Apellis Have Planned After Raising $170m from Pub…
August 24, 2017 Endpoints News On a roll, Apellis adds positive PhII C3 data for AMD drug, preps for PhIII